Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 5/20 | 0.44 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.41 |
| ▸ | PGR | P06401 | 1/20 | 0.41 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.41 |
| ▸ | AR | P10275 | 1/20 | 0.41 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.41 |
| ▸ | PLA2G7 | Q13093 | 3/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10626704 | 0.81 | PTGS2 (0.56) | PTGS2PTGS1PLA2G7 | |
| SCHEMBL15108250 | 0.79 | PLA2G7 (0.49) | PTGS2SLC22A12PTGS1NR3C1PGR | |
| SCHEMBL6663236 | 0.78 | ALDH1A1 (0.44) | PTGS2SLC22A12PTGS1CA2CA1 | |
| SCHEMBL4143797 | 0.78 | KIF11 (0.46) | PTGS2PTGS1ALDH1A1NR3C1PGR | |
| SCHEMBL13028793 | 0.78 | CA2 (0.41) | CA2CA1ADRB3 | |
| SCHEMBL16492686 | 0.78 | KMT2A (0.55) | PTGS2SLC22A12PTGS1CA2CA1 | |
| SCHEMBL3746873 | 0.77 | KIF11 (0.50) | SLC22A12CA2NR3C1 | |
| SCHEMBL28610415 | 0.77 | KEAP1 (0.54) | CA2CA1ALDH1A1 | |
| SCHEMBL17703732 | 0.76 | NR3C1 (0.43) | PTGS2SLC22A12PTGS1ALDH1A1NR3C1 | |
| SCHEMBL1688371 | 0.76 | PLA2G7 (0.49) | PTGS2SLC22A12PTGS1NR3C1PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2254864-B1 | SUBSTITUTED 4-AMINOCYCLOHEXANE DERIVATIVES FOR THE TREATMENT OF PAIN | GRUENENTHAL GMBH (DE) | 2014-05-14 | — | — | EP | disclosed |
| US-20090215725-A1 | Substituted 4-aminocyclohexane derivatives | GRUNENTHAL GMBH (DE) | 2009-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215725-A1 | Substituted 4-aminocyclohexane derivatives | OPRL1, OPRD1, OPRK1 | PTGS2 268/4885SLC22A12 1125/4885PTGS1 238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.